ArticleJournal of hematology & oncology2017

Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.

Melissa García-Caballero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.